Skip to main content

Rational Therapeutics for Infants and Children Workshop Summary (2000) / Chapter Skim
Currently Skimming:

Appendix A: Workshop Agenda
Pages 105-110

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 105...
... Shine, M.D., President, Institute of Medicine Statement of Objectives, Charge to Participants, Introductions Ronald W Estabrook, Ph.D., Roundtable Chair, Virginia Lazenby O'Hara Professor of Biochemistry, University of Texas Southwestern Medical Center SESSION I: Similarities and Dissimilarities in Physiology, Metabolism, and Disease States and Responses to Therapy Among Children and Adults Presentations in this session will address the uniqueness of children and how they are similar or dissimilar to adults with regard to physiology, drug metabolism, immunology, cognitive effects, and response to disease states and therapy.
Read the entire page →
From page 106...
... Food and Drug Administration 12:15 p.m. Lunch Break SESSION II: Pharmacokinetics and Pharmacodynamics in Children Versus Adults Presentations in Session II will identify new advances in biomedical science that are uniquely applicable to children and that could be applied to the development and testing of drugs and biologics for children.
Read the entire page →
From page 107...
... Ballow, Pharm.D., Director, Anti-Infective Research, Kaleida Health Millard Fillmore Hospital Rational Therapeutics for Childhood Asthma Stanley J Szefler, M.D., Helen Wohlberg and Henry Lambert Chair in Pharmacokinetics, Director of Clinical Pharmacology, National Jewish Medical and Research Center, and Professor of Pediatrics, and Pharmacology, University of Colorado Health Sciences Center Oncology David Poplack, M.D., Elise C
Read the entire page →
From page 108...
... Food and Drug Administration Prediction of Long-Term Effects on Postnatal Brain Development Mark Batshaw, M.D., Chair of Pediatrics, George Washington University Medical Center, and Director, Children's Research Institute, Children's National Medical Center Evaluating Biological Therapeutics in Pediatric Clinical Trials Karen Weiss, M.D., Director, Division of Clinical Trial Design and Analysis, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration Break
Read the entire page →
From page 109...
... House of Representatives 10:30 11:00 1 1:30 FDA Perspective on New Regulations Dianne Murphy, M.D., Associate Director for Pediatrics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration The Role of IRB and Data Safety Boards Susan Ellenberg, Ph.D., Division of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S.
Read the entire page →
From page 110...
... 3:00 3:30 Conclusions Murray Lumpkin, M.D., Deputy Director for Review Management, Center for Drug Evaluation and Research, U.S. Food and Drug Administration Closing Remarks Ronald Estabrook, Ph.D., Roundtable Chair Adjournment
Read the entire page →

Key Terms

  • pediatric clinical
  • rational therapeutics
  • clinical pharmacology
  • drug evaluation
  • children versus

  • clinical trials
  • versus adults
  • pediatric drug
  • drug action
  • oncology section

  • regulatory considerations
  • colorado health
  • defining surrogate
  • pediatrics baylor
  • trial design

  • national medical
  • industry perspective
  • southwestern medical
  • pediatric oncology
  • blue cross

  • pediatric trials
  • cognitive effects
  • biologics evaluation
  • sciences center
  • henry lambert

  • david poplack
  • roche pharmaceuticals
  • international pediatric
  • lambert chair
  • dianne murphy


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.